Dabur India Limited has received an Import Alert (IA) 66-40 from the United States Food and Drug Administration (US FDA) on June 10, 2026, for drugs manufactured at its Silvassa plant in Dadra and Nagar Haveli. Dabur received the notification at 3.29 a.m. on June 10, 2026, and disclosed the information to stock exchanges on June 11, 2026.
The US FDA had inspected the Silvassa facility and identified deficiencies related to data integrity and maintenance lapses. Dabur received inspectional observations and submitted responses to the US FDA. After reviewing the responses and the Establishment Inspection Report, the US FDA issued the import alert for private label products manufactured at the Silvassa plant.
Dabur stated the order concerns only a small part of the Silvassa operation related to private label products that generate insignificant revenue. Domestic products are not covered or impacted by this order. The plant continues to be operational. Dabur stated that no violation has been committed or alleged to be committed.
Dabur is continuing to engage with the US FDA by providing corrective and preventive action plans. Multiple internal and external independent third-party tests have shown no out-of-specification or other concerns with any of Dabur's products. Dabur is implementing alternate sourcing strategies for its US customers across its global operations.
The disclosure follows a prior communication from Dabur to the exchanges dated June 1, 2026. Dabur stated there is no impact on its financial, operational, or other activities from this order.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.